Akili, a leading digital medicine company, has reported a 37% increase in EndeavorRxⓇ prescriptions in Q4 2022 over Q3 2022, and a 166% increase in FY 2022 over FY 2021. This growth is supported by strong clinical data in adolescents with ADHD, which could lead to a potential label expansion for EndeavorRx. Akili plans to … Continue reading Akili’s Operating Plan for 2023 Focuses on EndeavorRx Commercialization and Growth